EP
DNLI icon

Essential Partners’s Denali Therapeutics DNLI Stock Holding History

Essential Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.07K Buy
236
+191
+424% +$3.92K ﹤0.01% 1451
2026
Q1 		$864 Buy
+45
New +$895 ﹤0.01% 2283

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's DNLI Position: Q2 2026 in Review

Essential Partners increased its Denali Therapeutics (DNLI) stake by 424% in Q2 2026, buying an estimated $3.92K and bringing the position to 236 shares worth $6.07K. The position accounts for ﹤0.01% of the portfolio, ranked #1451.

Essential Partners first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Essential Partners held 236 shares of Denali Therapeutics worth $6.07K as of Q2 2026.
  • Essential Partners bought 191 Denali Therapeutics shares in Q2 2026, an estimated $3.92K.
  • Denali Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1451 holding.
  • Essential Partners first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.